Literature DB >> 17177607

Cloning and nucleotide analysis of the vp2 gene of a very virulent infectious bursal disease virus isolate from Iran.

M Shamsara1, S A Ghorashi, G Ahmadian.   

Abstract

An Iranian field isolate (IR01) of Infectious bursal disease virus (IBDV) was characterized by sequence analysis of its VP2 gene and protein. Comparison of the obtained sequences with those of IBDV isolates from other countries revealed that IR01 was similar to very virulent IBDV (vvIBDV) strains with the identities at nucleotide and amino acid levels reaching 98.198.9% and 99.199.3%, respectively. On the other hand, it was less similar to non-vvIBDV strains; with nucleotide and amino acid identities of 95.295.7% and 96.097.3%, respectively. Out of nine unique nucleotide differences found between IR01 and some other serotype 1 strains only two resulted in amino acid substitutions (Ile296Val and Thr359Lys). In phylogenetic analysis, IR01 was closely related to Asian and European vvIBDV strains. Based on these results, IR01 obviously belongs to vvIBDV strains.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17177607

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  3 in total

1.  A potential nanobiotechnology platform based on infectious bursal disease subviral particles.

Authors:  Omid Taghavian; Manoj K Mandal; Nicole F Steinmetz; Stefan Rasche; Holger Spiegel; Rainer Fischer; Stefan Schillberg
Journal:  RSC Adv       Date:  2012-01-09       Impact factor: 3.361

2.  Fusion protein strategy to increase expression and solubility of hypervariable region of VP2 protein of infectious bursal disease virus in Escherichia coli.

Authors:  Sahar Sadat Sedighzadeh; Mehdi Shamsara; Azar Shahpiri
Journal:  Protein J       Date:  2012-10       Impact factor: 2.371

3.  Protective oral vaccination against infectious bursal disease virus using the major viral antigenic protein VP2 produced in Pichia pastoris.

Authors:  Omid Taghavian; Holger Spiegel; Rüdiger Hauck; Hafez M Hafez; Rainer Fischer; Stefan Schillberg
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.